201 related articles for article (PubMed ID: 24236082)
1. Combination of EGFR-TKIs and chemotherapy as first-line therapy for advanced NSCLC: a meta-analysis.
OuYang PY; Su Z; Mao YP; Deng W; Xie FY
PLoS One; 2013; 8(11):e79000. PubMed ID: 24236082
[TBL] [Abstract][Full Text] [Related]
2. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
Lee CK; Brown C; Gralla RJ; Hirsh V; Thongprasert S; Tsai CM; Tan EH; Ho JC; Chu da T; Zaatar A; Osorio Sanchez JA; Vu VV; Au JS; Inoue A; Lee SM; Gebski V; Yang JC
J Natl Cancer Inst; 2013 May; 105(9):595-605. PubMed ID: 23594426
[TBL] [Abstract][Full Text] [Related]
3. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.
Sugawara S; Oizumi S; Minato K; Harada T; Inoue A; Fujita Y; Maemondo M; Yoshizawa H; Ito K; Gemma A; Nishitsuji M; Harada M; Isobe H; Kinoshita I; Morita S; Kobayashi K; Hagiwara K; Kurihara M; Nukiwa T
Ann Oncol; 2015 May; 26(5):888-894. PubMed ID: 25669832
[TBL] [Abstract][Full Text] [Related]
5. The impact of smoking status on the progression-free survival of non-small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta-analysis.
Li X; Huang C; Xie X; Wu Z; Tian X; Wu Y; Du X; Shi L
J Clin Pharm Ther; 2021 Apr; 46(2):256-266. PubMed ID: 33152129
[TBL] [Abstract][Full Text] [Related]
6. Combination strategies based on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for cancer patients: Pooled analysis and subgroup analysis of efficacy and safety.
Xu R; Shao H; Zhu J; Ju Q; Shi H
Medicine (Baltimore); 2019 Mar; 98(13):e14135. PubMed ID: 30921175
[TBL] [Abstract][Full Text] [Related]
7. EGFR tyrosine kinase inhibitors alone or in combination with chemotherapy for non-small-cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials.
Zhu CM; Lian XY; Zhang HY; Bai L; Yun WJ; Zhao RH; Li QS
J Cancer Res Ther; 2021 Jul; 17(3):664-670. PubMed ID: 34269297
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of epidermal growth factor receptor inhibitors in combination with chemotherapy in advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Zhang M; Guo H; Zhao S; Wang Y; Yang M; Yu J; Yan Y; Wang Y
Oncotarget; 2016 Jun; 7(26):39823-39833. PubMed ID: 27223081
[TBL] [Abstract][Full Text] [Related]
9. Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients.
Yan H; Li Q; Wang W; Zhen H; Cao B
Sci Rep; 2015 Oct; 5():15355. PubMed ID: 26481697
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of EGFR tyrosine kinase inhibitors compared with chemotherapy as second-line treatment in pretreated advanced non-small cell lung cancer.
Li N; Yang L; Ou W; Zhang L; Zhang SL; Wang SY
PLoS One; 2014; 9(7):e102777. PubMed ID: 25029199
[TBL] [Abstract][Full Text] [Related]
11. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials.
Liu J; Sheng Z; Zhang Y; Li G
Target Oncol; 2016 Feb; 11(1):49-58. PubMed ID: 26206590
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Qi YT; Hou Y; Qi LC
Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
[TBL] [Abstract][Full Text] [Related]
13. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
14. A meta-analysis of the comparing of the first-generation and next-generation TKIs in the treatment of NSCLC.
Li YX; Yang JY; Xu YF; Zhang M; Zhang XP; Chen WY; Lv XD
Math Biosci Eng; 2019 Jun; 16(5):5687-5696. PubMed ID: 31499732
[No Abstract] [Full Text] [Related]
15. Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis.
Guetz GD; Landre T; Uzzan B; Chouahnia K; Nicolas P; Morere JF
Target Oncol; 2016 Feb; 11(1):41-7. PubMed ID: 26092590
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
[TBL] [Abstract][Full Text] [Related]
17. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs.
Sheng Z; Zhang Y
Am J Clin Oncol; 2017 Aug; 40(4):362-369. PubMed ID: 25647830
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of seven randomized control trials to assess the efficacy and toxicity of combining EGFR-TKI with chemotherapy for patients with advanced NSCLC who failed first-line treatment.
Xiao BK; Yang JY; Dong JX; Ji ZS; Si HY; Wang WL; Huang RQ
Asian Pac J Cancer Prev; 2015; 16(7):2915-21. PubMed ID: 25854383
[TBL] [Abstract][Full Text] [Related]
19. The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer.
Zhang JW; Zhao YY; Guo Y; Xue C; Hu ZH; Huang Y; Zhao HY; Zhang J; Wu X; Fang WF; Ma YX; Zhang L
Chin J Cancer; 2014 Feb; 33(2):105-14. PubMed ID: 23816558
[TBL] [Abstract][Full Text] [Related]
20. [Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis].
Hong C; Mei T; Wang J
Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):837-846. PubMed ID: 27978869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
